Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2025-07-01 00:00:00 ET · period of report 2025-06-30 · accession 0001562180-25-005201 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-07-01 | 2025-06-30 | AKBA | Ostrowski Erik | SVP, CFO, CBO, Treas | S - Sale | $3.67 | -41.3K | 503.6K | -8% | -$151.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-30 | S | D | 41,314 | $3.67 | 503,586 | D | — | — | (F2) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on June 28, 2024. (F1) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024. |